论文部分内容阅读
目的探讨凝血酶激活的纤溶抑制物活性(TAFI:A)和凝血酶-抗凝血酶复合物(TAT)水平与不同分期胃癌之间的关系。方法收集48例临床胃癌患者、34例同期住院的胃良性疾病患者和50名健康体检者的血液标本,采用发色底物法检测血浆中TAFI水平;ELISA法检测TAT水平;同时检测D-二聚体、纤维蛋白原,分析以上指标在不同分期胃癌的水平。通过受试者工作特征曲线(ROC曲线)分别评价TAFI和TAT的检验效能和最佳诊断分界值。结果与健康对照组及胃良性疾病组相比,胃癌病例组血浆TAFI、TAT、D-二聚体及纤维蛋白原水平均显著升高(P<0.05);胃良性疾病组与健康对照组上述指标的差异则无统计学意义(P>0.05)。血浆TAFI水平为28.85μg/mL时,灵敏度和特异性分别是0.646和0.869;TAT水平为31.50 ng/mL时,灵敏度和特异性分别是0.813和0.786。结论胃癌患者血浆TAFI和TAT水平显著升高是胃癌患者血栓形成倾向的标志,TAFI和TAT有望成为胃癌患病风险的预测指标。
Objective To investigate the relationship between thrombin-activated fibrinolysis inhibitor activity (TAFI: A) and thrombin-antithrombin complex (TAT) levels in gastric cancer with different stages. Methods 48 cases of gastric cancer patients clinically, 34 patients with benign gastric disease hospitalization period and 50 healthy blood samples, using the chromogenic substrate assay of plasma TAFI levels; TAT levels detected by ELISA; simultaneous detection of two D- Polymer, fibrinogen, analysis of the above indicators in different stages of gastric cancer levels. The performance of TAFI and TAT and the best diagnostic cutoff value were evaluated by receiver operating characteristic curve (ROC curve). Results The levels of plasma TAFI, TAT, D-dimer and fibrinogen in gastric cancer cases were significantly higher than those in healthy controls and gastric benign diseases group (P <0.05). The gastric ulcer disease group and healthy control group above indexes The difference was not statistically significant (P> 0.05). The sensitivity and specificity for plasma TAFI levels of 28.85 μg / mL were 0.646 and 0.869, respectively; for TAT levels of 31.50 ng / mL, the sensitivity and specificity were 0.813 and 0.786, respectively. Conclusion The significant increase of plasma TAFI and TAT in patients with gastric cancer is a marker of thrombosis tendency in patients with gastric cancer. TAFI and TAT are expected to be predictors of the risk of gastric cancer.